<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03330405</url>
  </required_header>
  <id_info>
    <org_study_id>B9991025</org_study_id>
    <secondary_id>2017-001509-33</secondary_id>
    <secondary_id>JAVELIN PARP MEDLEY</secondary_id>
    <nct_id>NCT03330405</nct_id>
  </id_info>
  <brief_title>Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Avelumab in combination with talazoparib will be investigated in patients with locally
      advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung
      cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast
      cancer, recurrent platinum sensitive ovarian cancer, urothelial cancer (UC), and castration
      resistant prostate cancer (CRPC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Avelumab is a human immunoglobulin (Ig)G1 monoclonal antibody (mAb) directed against
      programmed death ligand 1 (PD L1). Avelumab selectively binds to PD L1 and competitively
      blocks its interaction with programmed death receptor 1 (PD 1), thereby interfering with this
      key immune checkpoint inhibition pathway. Avelumab is currently being investigated as single
      agent and in combination with other anti cancer therapies in patients with locally advanced
      or metastatic solid tumors and various hematological malignancies.

      Talazoparib is a potent, orally bioavailable poly (adenosine diphosphate [ADP] ribose)
      polymerase (PARP) inhibitor, which is cytotoxic to human cancer cell lines harboring gene
      mutations that compromise deoxyribonucleic acid (DNA) repair, an effect referred to as
      synthetic lethality, and by trapping PARP protein on DNA thereby preventing DNA repair,
      replication, and transcription.

      Avelumab in combination with talazoparib will be investigated in patients with locally
      advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung
      cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast
      cancer, recurrent platinum sensitive ovarian cancer, urothelial cancer (UC), and castration
      resistant prostate cancer (CRPC).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2017</start_date>
  <completion_date type="Anticipated">March 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 28, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Cycle 1 Days 1-28 (28 days from date of first dose of study treatment)</time_frame>
    <description>Phase 1b: DLT during the DLT evaluation period (Cycle 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response (OR)</measure>
    <time_frame>From date of first dose of study treatment until the date of first documented disease progression or date of death from any cause, whichever comes first, assessed up to approximately 24 months</time_frame>
    <description>Phase 2: Confirmed OR, as assessed by the Investigator using RECIST v1.1 in patients with locally advanced or metastatic solid tumors and RECIST v1.1 and PCWG3 in patients with metastatic CRPC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of avelumab</measure>
    <time_frame>Day 1 Cycles 1-4, 6, 9, 12, 18, 24 and Day 15 Cycle 1</time_frame>
    <description>Pharmacokinetic parameters: pre-dose/trough concentrations (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti drug antibody (ADA) levels of avelumab</measure>
    <time_frame>Day 1 Cycles 1-4, 6,9,12,18, 24 and Day 15 Cycle 1</time_frame>
    <description>Immunogenicity assessment of avelumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OR</measure>
    <time_frame>From the start of treatment until disease progression/recurrence up to approximately 24 months</time_frame>
    <description>Phase 1b: Confirmed OR, as assessed by the Investigator using RECIST v1.1 in patients with locally advanced or metastatic solid tumors and RECIST v1.1 and PCWG3 in patients with metastatic CRPC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Tumor Marker</measure>
    <time_frame>Baseline, Day1 of each cycle (each cycle is 28 days), and End of Treatment ( up to approximately 24 months)</time_frame>
    <description>PSA response greater than or equal to 50% for patients with metastatic CRPC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA-125 Tumor Marker</measure>
    <time_frame>Baseline, Day1 of each cycle (each cycle is 28 days), and End of Treatment (up to approximately 24 months)</time_frame>
    <description>CA-125 response for patients with ovarian cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker PD-L1</measure>
    <time_frame>Baseline</time_frame>
    <description>PD-L1 expression level in baseline tumor tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genomic</measure>
    <time_frame>Baseline</time_frame>
    <description>Genomic scarring and the presence of defects in select genes, considered critical to effective DDR, in baseline tumor tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of avelumab</measure>
    <time_frame>Day 1 Cycles 1-4, 6,9,12,18, 24 and Day 15 Cycle 1</time_frame>
    <description>Pharmacokinetic parameters: maximum concentrations (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of talazoparib</measure>
    <time_frame>Day 1 Cycles 1-4 and Day 15 Cycle 1</time_frame>
    <description>Pharmacokinetic parameters: pre-dose/trough concentrations (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of talazoparib</measure>
    <time_frame>Day 1 Cycles 1-4 and Day 15 Cycle 1</time_frame>
    <description>Pharmacokinetic parameters: post-dose concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibodies (Nab) levels against avelumab.</measure>
    <time_frame>Day 1 Cycles 1-4, 6, 9, 12, 18, 24 and Day 15 Cycle 1</time_frame>
    <description>Immunogenicity assessment of avelumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Response (TTR)</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <description>Time to Tumor Response (TTR) is defined for patients with confirmed objective response (CR or PR) as the time from the first dose of study treatment to the first documentation of objective tumor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DR)</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <description>Duration of Response (DR) is defined for patients with confirmed objective response (complete response [CR] or partial response [PR]) as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <description>Progression Free Survival (PFS) is defined as the time from the first dose of study treatment to the date of disease progression by RECIST v1.1 or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-Specific Antigen (PSA) response</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <description>PSA response is defined as the proportion of patients with confirmed PSA decline greater than or equal to 50% compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <description>OS is defined as the time from the first dose of study treatment to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Tumor Mutational Burden</measure>
    <time_frame>Baseline</time_frame>
    <description>Tumor mutational burden in baseline tumor tissue</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Level 0 Phase 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Avelumab
Drug: Talazoparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level -1 Phase 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Avelumab
Drug: Talazoparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level -2 Phase 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Avelumab
Drug: Talazoparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A1. NSCLC Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Avelumab
Drug: Talazoparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2. NSCLC PD-L1+ Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Avelumab
Drug: Talazoparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1. TNBC Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Avelumab
Drug: Talazoparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2. HR+BC DDR Defect +Assay Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Avelumab
Drug: Talazoparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1. Ovarian CA Recurrent Plat-Sensitive Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Avelumab
Drug: Talazoparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2.Ovarian CA Recurrent Plat-Sensitive BRCA defect Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Avelumab
Drug: Talazoparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D.Urothelial CA Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Avelumab
Drug: Talazoparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E1. CRPC Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Avelumab
Drug: Talazoparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E2. CRPC DDR Defect +Assay Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Avelumab
Drug: Talazoparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F: Advanced Solid Tumors with BRCA or ATM defect Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Avelumab
Drug: Talazoparib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab Phase 1b</intervention_name>
    <description>Avelumab</description>
    <arm_group_label>Dose Level 0 Phase 1b</arm_group_label>
    <arm_group_label>Dose Level -1 Phase 1b</arm_group_label>
    <arm_group_label>Dose Level -2 Phase 1b</arm_group_label>
    <other_name>MSB0010718C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talazoparib Phase 1b</intervention_name>
    <description>Talazoparib</description>
    <arm_group_label>Dose Level 0 Phase 1b</arm_group_label>
    <arm_group_label>Dose Level -1 Phase 1b</arm_group_label>
    <arm_group_label>Dose Level -2 Phase 1b</arm_group_label>
    <other_name>MDV3800, BMN 673</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab Phase 2</intervention_name>
    <description>The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.</description>
    <arm_group_label>A1. NSCLC Phase 2</arm_group_label>
    <arm_group_label>A2. NSCLC PD-L1+ Phase 2</arm_group_label>
    <arm_group_label>B1. TNBC Phase 2</arm_group_label>
    <arm_group_label>B2. HR+BC DDR Defect +Assay Phase 2</arm_group_label>
    <arm_group_label>C1. Ovarian CA Recurrent Plat-Sensitive Phase 2</arm_group_label>
    <arm_group_label>C2.Ovarian CA Recurrent Plat-Sensitive BRCA defect Phase 2</arm_group_label>
    <arm_group_label>D.Urothelial CA Phase 2</arm_group_label>
    <arm_group_label>E1. CRPC Phase 2</arm_group_label>
    <arm_group_label>E2. CRPC DDR Defect +Assay Phase 2</arm_group_label>
    <arm_group_label>F: Advanced Solid Tumors with BRCA or ATM defect Phase 2</arm_group_label>
    <other_name>MSB0010718C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talazoparib Phase 2</intervention_name>
    <description>The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.</description>
    <arm_group_label>A1. NSCLC Phase 2</arm_group_label>
    <arm_group_label>A2. NSCLC PD-L1+ Phase 2</arm_group_label>
    <arm_group_label>B1. TNBC Phase 2</arm_group_label>
    <arm_group_label>B2. HR+BC DDR Defect +Assay Phase 2</arm_group_label>
    <arm_group_label>C1. Ovarian CA Recurrent Plat-Sensitive Phase 2</arm_group_label>
    <arm_group_label>C2.Ovarian CA Recurrent Plat-Sensitive BRCA defect Phase 2</arm_group_label>
    <arm_group_label>D.Urothelial CA Phase 2</arm_group_label>
    <arm_group_label>E1. CRPC Phase 2</arm_group_label>
    <arm_group_label>E2. CRPC DDR Defect +Assay Phase 2</arm_group_label>
    <arm_group_label>F: Advanced Solid Tumors with BRCA or ATM defect Phase 2</arm_group_label>
    <other_name>MDV3800, BMN 673</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid
             tumors that are not amenable for treatment with curative intent in adult patients
             with: NSCLC, TNBC, HR+ breast cancer, recurrent platinum sensitive ovarian cancer, UC,
             CRPC, and other advanced solid tumors with a BRCA or ATM gene defect

          -  Mandatory primary or metastatic tumor biopsy. If archival tumor tissue is available
             from a biopsy/surgery the tumor tissue may be submitted without repeating a tumor
             biopsy during the screening period.

          -  Minimum age in Japan is 20 years.

          -  ECOG performance status 0 or 1.

          -  Resolved acute effects of prior therapy

          -  Adequate bone marrow, renal, and liver function.

          -  Negative serum pregnancy test at screening.

          -  Male and female patients able to have children must agree to use 2 effective methods
             of contraception throughout the study and for up to 45 days for female patients and
             105 days for male patients after the last dose.

          -  Signed and dated informed consent.

        Exclusion Criteria:

          -  Prior treatment with a PARP inhibitor.

          -  Prior immunotherapy with IL-2, IFN-Î±, or an anti-PD-1, anti-PD-L1, anti-PD-L2,
             anti-CD137, OX 40, GITR, LAG 3, IDO, TDO,TIM 3, CTLA-4 antibody, or any other antibody
             or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
             Prior treatment with Sipuleucel-T for patients with mCRPC is allowed.

          -  Prior anti-cancer therapy within 4 weeks prior to study enrollment. Prior radiation
             therapy within 2 weeks prior to enrollment. Prior palliative radiotherapy to
             metastatic lesion(s) is permitted, provided it has been completed 2 days prior to
             study enrollment and no clinically significant toxicities are expected (eg, mucositis,
             esophagitis).

          -  Major surgery within 4 weeks prior to study enrollment.

          -  Current use of immunosuppressive medication at the time of study enrollment.

          -  Known prior or suspected hypersensitivity to investigational products.

          -  Known history of immune mediated colitis, inflammatory bowel disease, pneumonitis,
             pulmonary fibrosis.

          -  Active or prior autoimmune disease that might deteriorate when receiving an
             immunostimulatory agent.

          -  Prior organ transplantation including allogenic stem-cell transplantation.

          -  Vaccination within 4 weeks of study enrollment and while on trial is prohibited except
             for administration of inactivated vaccines.

          -  Diagnosis of Myelodysplastic Syndrome.

          -  Patients with known brain metastases requiring steroids.

          -  Participation in other studies involving investigational drug(s) within 4 weeks prior
             to study participation and/or during study participation.

          -  Persisting toxicity related to prior therapy &gt;Grade 1

          -  Known HIV or AIDs-related illness.

          -  Positive HBV or HCV test indicating acute or chronic infection.

          -  Active infection requiring systemic therapy.

          -  Clinically significant cardiovascular disease: cerebral vascular accident/stroke or
             myocardial infarction within 6 months prior to study entry; unstable angina,
             congestive heart failure or a serious cardiac arrhythmia requiring medication.

          -  Current or anticipated use of a P glycoprotein (P gp) inhibitor (eg, dronedarone,
             quinidine, ranolazine, itraconazole, ketoconazole), strong P gp inducer (eg, rifampin,
             ritonavir, tipranavir), or strong inhibitor of breast cancer resistance protein (BCRP)
             (eg, elacridar [GF120918]).

          -  Other acute or chronic medical or psychiatric conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital (MGH)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ship drug to: Massachusetts General Hospital Attn: Svetlana Rashkova</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ship Drug to: Dana Farber Cancer Institute, Attn: Vasilika Koci, PharmD</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Investigational Pharmacy</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Laura and Isaac Perlmutter Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital- Pharmacy department</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center Investigational Pharmacy</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B9991025&amp;StudyName=A+Phase+1b%2F2+Study+To+Evaluate+Safety+And+Anti-tumor+Activity+Of+Avelumab+In+Combination+With+The+Poly+%28adenosine+Diphosphate+%5Badp%5D-ribose%29+Polymerase+%28parp%29+Inhibitor+Talazoparib+In+Patients+With+Locally+Advanced+Or+Metastatic+Solid+Tumors</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B9991025&amp;StudyName=A+Phase+1b%2F2+Study+To+Evaluate+Safety+And+Anti+Tumor+Activity+Of+Avelumab+In+Combination+With+The+Poly%28adenosine+Diphosphate+%5Badp%5D-ribose%29+Polymerase+%28parp%29+Inhibitor+Talazoparib+In+Patients+With+Locally+Advanced+Or+Metastatic+Solid+Tumors</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC, TNBC, hormone receptor positive (HR+) breast cancer, recurrent epithelial ovarian cancer, UC, and castration resistant prostate cancer (CRPC).</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Talazoparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

